RETA Short Information, Reata Pharmaceuticals Inc.

Twenty Trading Day Totals
Total Shorted Volume	807,782
Total Actual Volume	5,325,128

Averages
Average Short Volume	40,389
Average Short Percentage	52.39%

Is there a RETA Short Squeeze or Breakout about to happen?

See the RETA Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2021-01-20	114.12	110	115.82	109.7	299,697	35,341	53.3135
2021-01-19	114.85	113.84	117.75	112.22	311,743	47,694	65.0154
2021-01-15	120.98	111.93	121.715	111.8	398,827	51,947	43.6768
2021-01-14	120.88	120	122.89	119.46	204,018	34,919	62.3131
2021-01-13	126.59	121.27	127.9	120.78	159,608	20,820	48.9710
2021-01-12	127.94	125.96	130.43	124.52	177,635	19,366	53.8723
2021-01-11	120.42	126.51	129.87	119.95	352,639	50,220	58.1998
2021-01-08	126.22	120.51	129.42	118.34	409,719	61,822	54.8520
2021-01-07	114.15	125	126.12	114.06	312,562	47,684	51.5865
2021-01-06	117.52	113.1	118.43	112.01	359,275	46,891	44.9036
2021-01-05	121.55	118.6	121.98	116.95	236,065	27,889	31.4558
2021-01-04	122.56	121.29	124.03	119.65	153,497	17,631	50.2107
2020-12-31	124.82	123.62	125.45	121.5525	178,941	14,090	31.1251
2020-12-30	130.14	125.01	131.22	124.365	250,603	57,505	63.9911
2020-12-29	129.07	129.73	130.465	124.64	258,208	56,037	61.0811
2020-12-28	134.11	129.3	135.58	128.2009	319,677	64,285	56.8904
2020-12-24	127.32	132.55	133.2	126.8048	212,811	48,654	64.6702
2020-12-23	125.01	127.15	127.53	124.2325	290,063	46,944	47.8688
2020-12-22	121.85	124.64	124.75	121.3656	213,629	26,586	51.6424
2020-12-21	120.65	120.66	122	117.7	225,911	31,457	52.1130

Stock Information

Reata Pharmaceuticals Inc. Company Name:

RETA Stock Symbol:

NASDAQ Market:

RETA Short Information, Reata Pharmaceuticals Inc.

Get RETA Alerts

News, Short Squeeze, Breakout and More Instantly...

RETA - Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Offering

PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,00...
RETA - Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering

PLANO, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a public offering of 2,000,000 shares by the Company of its Class...
RETA - Reata Provides Update on Omaveloxolone Program for Patients with Friedreich's Ataxia

PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”...